UBS analyst Eliana Merle initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $28 price target Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300, in development for bladder cancer and a genetic form of short stature, achondroplasia, with many health complications, the analyst tells investors in a research note. The firm thinks TYRA-300 could have improved efficacy and safety vs. Fibroblast Growth Factor Receptor inhibitors that also inhibit FGFR1, 2 and 4, and thinks the long-term opportunity for TYRA-30 in both oncology and growth disorders beyond achondroplasia is larger than appreciated.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TYRA:
- Tyra Biosciences price target lowered to $29 from $31 at BofA
- Tyra Biosciences price target lowered to $30 from $32 at H.C. Wainwright
- Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience
- Tyra Biosciences reports Q3 EPS (41c), consensus (40c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
